Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dorastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 17/20 | 0.80 |
| ▸ | HRH1 known ✓ | P35367 | 16/20 | 0.80 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.80 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.80 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.80 |
| ▸ | HTR7 known ✓ | P34969 | 3/20 | 0.80 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.80 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.80 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.80 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.80 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.80 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.80 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.80 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.80 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.80 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.80 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.80 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.80 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.80 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dorastine SCHEMBL3116611 | 0.99 | HTR6 (0.81) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| Dorastine SCHEMBL29387736 | 0.99 | HTR6 (0.81) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| Dorastine SCHEMBL3264836 | 0.95 | HRH1 (0.89) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL13696101 | 0.93 | HTR6 (0.72) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL13293404 | 0.92 | HRH1 (0.70) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| Dorastine SCHEMBL3121653 | 0.92 | ALDH1A1 (0.77) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3610808 | 0.91 | ALDH1A1 (0.76) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL12820293 | 0.91 | HTR6 (0.68) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL3733639 | 0.90 | HRH1 (0.98) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL29717582 | 0.90 | HRH1 (0.98) | HTR6HRH1ADRA2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382574-A1 | METHODS AND COMPOSITIONS FOR ORALLY DOSING ANIMALS | Animal Science Products, Inc. (US) | 2024-11-21 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-10624877-B2 | Composition and method for treatment of symptoms associated with various skin conditions | THERACEUTIX, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190054024-A1 | Solid Dosage Forms | HUMANWELL PHARMACEUTICAL US, Inc. (US) | 2019-02-21 | — | — | US | disclosed |
| US-20180133196-A1 | COMPOSITION AND METHOD FOR TREATMENT OF SYMPTOMS ASSOCIATED WITH VARIOUS SKIN CONDITIONS | THERACEUTIX, LLC | 2018-05-17 | — | — | US | disclosed |
| US-9968590-B2 | Composition and method for treatment of symptoms associated with various skin conditions | THERACEUTIX, LLC (US) | 2018-05-15 | — | — | US | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | LUITPOLD PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| US-6267957-B1 | Attaching agents to tissue with transglutaminase and a transglutaminase substrate | PERICOR SCIENCE, INC. | 2001-07-31 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2001007009-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001006829-A2 | LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1054998-A1 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000040604-A2 | METHODS AND COMPOSITIONS FOR MODULATING CYTOKINE RELEASE BY αEβ7-EXPRESSING CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-1999036570-A2 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE INC (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | FABP7, FADS2, ALOX5 | HTR6 782/4885HRH1 2347/4885ADRA2A 946/4885 |
| US-10624877-B2 | Composition and method for treatment of symptoms associated with various skin conditions | OAT, CUTA, KRT18 | HTR6 1963/4885HRH1 351/4885ADRA2A 3262/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | HTR6 604/4885HRH1 1088/4885ADRA2A 639/4885 |
| US-20180133196-A1 | COMPOSITION AND METHOD FOR TREATMENT OF SYMPTOMS ASSOCIATED WITH VARIOUS SKIN CONDITIONS | OAT, CUTA, KRT18 | HTR6 1963/4885HRH1 351/4885ADRA2A 3262/4885 |
| US-20170216314-A1 | TOPICAL FORMULATIONS | SMURF1, SGMS1, SPTLC1 | HTR6 1333/4885HRH1 4592/4885ADRA2A 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.